Cocrystal Pharma (COCP) Projected to Release Quarterly Earnings on Friday

Cocrystal Pharma (NASDAQ:COCP) is anticipated to post its results on Friday, November 13th. Analysts expect Cocrystal Pharma to announce earnings of ($0.17) per share and revenue of $0.10 million for the quarter.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts expect Cocrystal Pharma to post ($0.69) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Cocrystal Pharma Trading Down 6.8%

NASDAQ COCP opened at $1.03 on Wednesday. The company’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.10. The stock has a market cap of $19.84 million, a PE ratio of -1.36 and a beta of 1.60. Cocrystal Pharma has a 12 month low of $0.76 and a 12 month high of $2.03.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Weiss Ratings lowered shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. HC Wainwright reissued a “buy” rating on shares of Cocrystal Pharma in a research report on Friday, October 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cocrystal Pharma presently has a consensus rating of “Hold”.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics. The company uses structure-based drug discovery and advanced medicinal chemistry to design small-molecule treatments intended to target viral replication mechanisms. Cocrystal’s research and development programs have focused primarily on infectious diseases, including influenza A and norovirus. Its pipeline has included orally administered antiviral candidates designed to inhibit viral polymerase proteins, as well as programs addressing other significant viral pathogens.